Selective accumulation of an exogenous enzyme or activating agent at a target cell allows
use of prodrugs that will be unmasked only at this site. This can reduce the side effects of …

Over the last years, a novel class of anti-cancer drugs named antibody-drug conjugates
(ADCs) has been developed. Due to their limited off-target toxicity but highly potent …

In this review glycosidase activated prodrugs that target cancer cells are discussed.
Glycosylated prodrugs undergo enzymatic bioconversion, cleaving the prodrug to release …

It is estimated that about 10% of the drugs approved worldwide can be classified as
prodrugs. Prodrugs, which have no or poor biological activity, are chemically modified …

Strategies that promote selective activation of prodrugs by enzymes can be divided into two
major classes: 1) deliver of a monoclonal antibody-enzyme immunoconjugate that can …

Since the end of 2008, there has been a spurt of investment and interest in the development
of follow-on biologics, or biosimilars, by both biopharmaceutical and generic-drug …

The efficacy of cancer chemotherapy is frequently hampered by a low therapeutic index.
Recently, strategies have been developed to improve this index by selective delivery of …

The goal for successful anticancer agents has been to design drugs with intrinsic specificity
for specific types of cancer cells. Unfortunately, their efficacy is often hampered by an …

Antibody-directed enzyme prodrug therapy (ADEPT) is a system that aims to restrict the
action of a high concentration of a cytotoxic drug to cancer sites. This is achieved by using …

The treatment of cancer with common anti-proliferative agents generally suffers from an
insufficient differentiation between normal and malignant cells which results in extensive …